Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Urinalysis instrumentation, 2023

[one_third]

[/one_third]

[one_third]

[/one_third]

[one_third_last]

[/one_third_last]

[wpdatatable id=67]

[one_third]


[/one_third]

[two_third_last]

In urinalysis, reflex algorithms and other efficiencies

March 2023—Urinalysis was at the heart of a Feb. 7 discussion between CAP TODAY publisher Bob McGonnagle; Ron Jackups Jr., MD, PhD, of Washington University School of Medicine; and Jason Anderson of Sysmex America. “There’s a lot of room to explore what the optimal parameters are to use with the best specificity and sensitivity for a reflex to the sediment analysis or the culture,” Anderson said. Here’s what he and Dr. Jackups said about reflex testing, automation, and middleware.

Since the urinalysis roundtable in December 2021, three things continue to be hot issues regardless of instrumentation, field of analysis, and subspecialty. Number one is automation in workflow, having something that’s robust for high volume, low staffing. Number two is the need for fit of an instrument line. In other words, there’s a core lab urinalysis instrument that’s ideal and yet there are smaller clinics, hospitals, all kinds of sites that can benefit from the same technology but in a differently configured unit. Number three is understanding if we’re extracting the optimum clinical information from the analysis in fields like hematology and urinalysis.

Dr. Jackups

Ron Jackups, talk to us about reflex testing in urinalysis and then more specifically about what you’ve been working on at Barnes-Jewish Hospital.
Ron Jackups Jr., MD, PhD, associate professor of pathology and immunology, Washington University School of Medicine, and associate chief medical information officer for laboratory informatics, BJC HealthCare: Reflex testing in general has two big benefits. The first is it focuses the diagnostic process, which reduces waste. We have seen in urinalysis and other areas that providers, rather than order a test and wait for the result and then order another test based on that result and wait for the next result, et cetera, tend to do what we call shotgun testing—they order all the tests they think might be relevant at once and then react to the results after they get them. This is wasteful in many situations if the tests further down the line were not necessary and can also be dangerous if one of the tests down the line is a false-positive. Part of the goal of reflex testing is to identify situations where there’s a low diagnostic value and high risk of false-positives in future tests that could be prevented by simply not doing them. That’s the first reason to do reflex testing.
Continue reading …
[/two_third_last]